Conatus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Conatus and buy or sell other stocks, ETFs, and their options commission-free!

About CNAT

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. 

CEO
Steven J. Mento, PhD
CEOSteven J. Mento, PhD
Employees
Employees
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2005
Founded2005
Employees
Employees

CNAT Key Statistics

Market cap
Market cap
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.19
52 Week high$0.19
52 Week low
$0.0002
52 Week low$0.0002

Stock Snapshot

The current Conatus(CNAT) stock price is $0.56.

During the trading day, Conatus(CNAT) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0.

Over the past 52 weeks, Conatus(CNAT) stock has traded between a high of $0.19 and a low of $0.00.

Over the past 52 weeks, Conatus(CNAT) stock has traded between a high of $0.19 and a low of $0.00.

People also own

Based on the portfolios of people who own CNAT. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.